Quoin Pharmaceuticals Ltd Stock Today
| QNRX Stock | USD 15.05 2.96 24.48% |
PerformanceFair
| Odds Of DistressStrong
|
Quoin Pharmaceuticals is trading at 15.05 as of the 9th of December 2025; that is 24.48 percent increase since the beginning of the trading day. The stock's open price was 12.09. Quoin Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 9th of November 2025 and ending today, the 9th of December 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of July 2016 | Category Healthcare | Classification Health Care |
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Quoin Pharmaceuticals, Ltd. was incorporated in 2018 and is based in Ashburn, Virginia. The company has 838.98 K outstanding shares of which 130.35 K shares are at this time shorted by private and institutional investors with about 0.14 trading days to cover. More on Quoin Pharmaceuticals Ltd
Moving together with Quoin Stock
| 0.82 | GILD | Gilead Sciences Sell-off Trend | PairCorr |
Moving against Quoin Stock
Quoin Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsQuoin Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Quoin Pharmaceuticals' financial leverage. It provides some insight into what part of Quoin Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quoin Pharmaceuticals Ltd (QNRX) is traded on NASDAQ Exchange in USA and employs 3 people. Quoin Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.14 M. Quoin Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 838.98 K outstanding shares of which 130.35 K shares are at this time shorted by private and institutional investors with about 0.14 trading days to cover.
Quoin Pharmaceuticals Ltd currently holds about 2.69 M in cash with (7.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56.
Check Quoin Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Quoin Pharmaceuticals is $10.14 Million. Quoin Pharmaceuticals holds 6.82 pct. of its outstanding shares held by insiders and 3.86 pct. owned by third-party entities. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Quoin Ownership Details
Quoin Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Boothbay Fund Management, Llc | 2025-03-31 | 0.0 | |
| Hrt Financial Llc | 2025-03-31 | 0.0 | |
| Rhumbline Advisers | 2025-06-30 | 1.2 K | |
| Gamma Investing Llc | 2025-06-30 | 240 | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 206 | |
| Ubs Group Ag | 2025-06-30 | 130 | |
| Sbi Securities Co Ltd | 2025-06-30 | 2.0 | |
| Altium Capital Management, Lp | 2025-03-31 | 0.0 | |
| Ikarian Capital, Llc | 2025-03-31 | 0.0 | |
| Renaissance Technologies Corp | 2025-03-31 | 0.0 | |
| Armistice Capital, Llc | 2025-03-31 | 0.0 |
Quoin Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Quoin Pharmaceuticals market risk premium is the additional return an investor will receive from holding Quoin Pharmaceuticals long position in a well-diversified portfolio.
| Mean Deviation | 9.65 | |||
| Semi Deviation | 9.37 | |||
| Standard Deviation | 21.49 | |||
| Variance | 461.95 |
Quoin Stock Against Markets
Quoin Pharmaceuticals Corporate Management
| Michael Myers | CEO CoFounder | Profile | |
| Gordon JD | Chief Officer | Profile | |
| Denise Carter | COO CoFounder | Profile | |
| Sally Lawlor | Chief Officer | Profile |
Additional Tools for Quoin Stock Analysis
When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.